Provided by Tiger Trade Technology Pte. Ltd.

Summit Therapeutics PLC

16.91
+0.52003.17%
Post-market: 16.920.0100+0.06%19:58 EDT
Volume:13.06M
Turnover:224.22M
Market Cap:13.49B
PE:-15.13
High:17.72
Open:16.59
Low:16.17
Close:16.39
52wk High:29.23
52wk Low:12.07
Shares:797.75M
Float Shares:152.34M
Volume Ratio:1.41
T/O Rate:8.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1177
EPS(LYR):-1.4439
ROE:-192.50%
ROA:-101.61%
PB:21.41
PE(LYR):-11.71

Loading ...

Press Release: Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026

Dow Jones
·
Jul 16

Summit Therapeutics Schedules Q2 2026 Results, Operational Update Call

Reuters
·
Jul 16

The Bull Case For Summit Therapeutics (SMMT) Could Change Following Ridinilazole Sale And Royalty Deal

Simply Wall St.
·
Jul 15

Summit Therapeutics Divests Ridinilazole Asset to AI Biopharma Biossil

MT Newswires Live
·
Jul 14

Summit Therapeutics Signs Agreement to Sell Phase Iii Asset Ridinilazole to Biossil, Inc.

THOMSON REUTERS
·
Jul 14

Summit Therapeutics - to Receive $500,000 Upfront and up to $104.5 Mln in Milestones Plus Tiered Royalties

THOMSON REUTERS
·
Jul 14

Has Summit Therapeutics (SMMT) Become Undervalued As It Pulls Its $500 Million Offering?

Simply Wall St.
·
Jun 25

UK Vehicle Production Rebounds in May, Halting Four-Month Decline

Deep News
·
Jun 25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Damora Therapeutics (DMRA), Summit Therapeutics (SMMT) and Elicio Therapeutics (ELTX)

TIPRANKS
·
Jun 22

Summit Therapeutics shareholders approve 8 million-share increase to 2020 stock incentive plan

Reuters
·
Jun 13

Summit Therapeutics Co-CEO Mahkam Zanganeh reports purchase of 3,810,000 shares for $49.99 million

Reuters
·
Jun 13

Summit Therapeutics co-CEO Robert W. Duggan acquires 3,810,000 shares for $49.99 million

Reuters
·
Jun 13

Summit Therapeutics Withdraws Public Offering Due to Market Conditions

MT Newswires Live
·
Jun 11

Summit Therapeutics withdraws proposed underwritten public offering

TIPRANKS
·
Jun 11

BUZZ-Summit Therapeutics rebounds after pulling stock offering

Reuters
·
Jun 11

BRIEF-Summit Therapeutics Withdraws Proposed Underwritten Public Offering Effective- SEC Filing

Reuters
·
Jun 11

Summit Therapeutics - No Securities to Be Sold in Proposed Underwritten Public Offering - SEC Filing

THOMSON REUTERS
·
Jun 11

Summit Therapeutics Stock Slides to 52-Week Low on Plans for Secondary Offering

Dow Jones
·
Jun 11

Summit Therapeutics falls -10.2%

TIPRANKS
·
Jun 11

Summit Therapeutics put volume heavy and directionally bearish

TIPRANKS
·
Jun 10